Serum Levels of Hepatitis B Surface Antigen and DNA Can Predict Inactive Carriers With Low Risk of Disease Progression

Hepatology

Volumn 64, Issue 2, 2016, Pages 381-389

  Liu, Jessica ^a   Yang, Hwai I ^a   Lee, Mei Hsuan ^b   Jen, Chin Lan ^a   Batrla Utermann, Richard ^c   Lu, Sheng Nan ^d   Wang, Li Yu ^e   You, San Lin ^f   Chen, Chien Jen ^a,g  

^a GENOMICS RESEARCH CENTER   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^e MACKAY MEDICAL COLLEGE   (Taiwan)

^f FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^g NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; VIRUS DNA;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CHRONIC HEPATITIS B; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; HAZARD RATIO; HEPATITIS B VIRUS; HEPATITIS B VIRUS GENOTYPE B; HEPATITIS B VIRUS GENOTYPE C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTIVE VALIDITY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SEROLOGY; SERUM; VIRAL CLEARANCE; VIRUS CARRIER;

EID: 84979009871     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28552     Document Type: Article

References (30)

1. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008;359:1486-1500.
2. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-185.
3. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002;347:168-174.
4. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-662.
5. Tseng TC, Liu CJ, Chen CL, Wang CC, Su TH, Kuo SF, et al. Serum hepatitis B virus-DNA levels correlate with long-term adverse outcomes in spontaneous hepatitis B e antigen seroconverters. J Infect Dis 2012;205:54-63.
6. Chen CF, Lee WC, Yang HI, Chang HC, Jen CL, Iloeje UH, et al. Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma. Gastroenterology 2011;141:1240-1248.
7. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73.
8. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-686.
9. Liu J, Yang HI, Lee MH, Lu SN, Jen CL, Wang LY, et al. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology 2010;139:474-482.
10. Volz T, Lutgehetmann M, Wachtler P, Jacob A, Quaas A, Murray JM, et al. Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients. Gastroenterology 2007;133:843-852.
11. Liu J, Lee MH, Batrla-Utermann R, Jen CL, Iloeje UH, Lu SN, et al. A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection. J Hepatol 2013;58:853-860.
12. Liu J, Yang HI, Lee MH, Batrla-Utermann R, Jen CL, Lu SN, et al. Distinct seromarkers predict different milestones of chronic hepatitis B progression. Hepatology 2014;60:77-86.
13. Liu J, Tseng TC, Yang HI, Lee MH, Batrla-Utermann R, Jen CL, et al. Predicting HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients: external validation of a scoring system. J Infect Dis 2014. doi: 10.1093/infdis/jiu659.
14. Lee MH, Yang HI, Liu J, Batrla-Utermann R, Jen CL, Iloeje UH, et al. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles. Hepatology 2013;58:546-554.
15. Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 2012;142:1140-1149.e3.
16. Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, Yurdaydin C, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009;49:1141-1150.
17. Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, Martinot-Peignoux M, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009;49:1151-1157.
18. Brunetto MR, Oliveri F, Colombatto P, Moriconi F, Ciccorossi P, Coco B, et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 2010;139:483-490.
19. Martinot-Peignoux M, Lapalus M, Laouenan C, Lada O, Netto-Cardoso AC, Boyer N, et al. Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA. J Clin Virol 2013;58:401-407.
20. Chen CJ, Iloeje UH, Yang HI. Long-term outcomes in hepatitis B: the REVEAL-HBV study. Clin Liver Dis 2007;11:797-816.
21. Moucari R, Marcellin P. Quantification of hepatitis B surface antigen: a new concept for the management of chronic hepatitis B. Liver Int 2011;31(Suppl 1):122-128.
22. Moucari R, Martinot-Peignoux M, Mackiewicz V, Boyer N, Ripault MP, Castelnau C, et al. Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a. Antivir Ther 2009;14:1183-1188.
23. Thompson AJ, Nguyen T, Iser D, Ayres A, Jackson K, Littlejohn M, et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 2010;51:1933-1944.
24. Tseng TC, Liu CJ, Su TH, Wang CC, Chen CL, Chen PJ, et al. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology 2011;141:517-525.
25. Nguyen T, Thompson AJ, Bowden S, Croagh C, Bell S, Desmond PV, et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol 2010;52:508-513.
26. Su TH, Hsu CS, Chen CL, Liu CH, Huang YW, Tseng TC, et al. Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B. Antivir Ther 2010;15:1133-1139.
27. Jaroszewicz J, Calle Serrano B, Wursthorn K, Deterding K, Schlue J, Raupach R, et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 2010;52:514-522.
28. Sugiyama M, Tanaka Y, Kato T, Orito E, Ito K, Acharya SK, et al. Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens. Hepatology 2006;44:915-924.
29. Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004;126:1750-1758.
30. Nguyen T, Desmond P, Locarnini S. The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis B. Hepatol Int 2009;3:5-15.